CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Phase III Trial of Consolidation Therapy With Bortezomib (Velcade®)-Lenalidomide (Revlimid®) -Dexamethasone (VRD) Versus Bortezomib (Velcade®)-Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00522392
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:53.500950+00:00
Published At: 2015-06-26T00:00:00+00:00
Record Updated At: 2015-06-26
Results Posted At: 2015-06-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2015-06-26"
protocolSection.identificationModule.nctId: "NCT00522392"
protocolSection.identificationModule.officialTitle: "Randomized Phase III Trial of Consolidation Therapy With Bortezomib (Velcade\u00ae)-Lenalidomide (Revlimid\u00ae) -Dexamethasone (VRD) Versus Bortezomib (Velcade\u00ae)-Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2015-06-26"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.